

UNITED STATES PATENT AND TRADEMARK OFFICE
BOARD OF PATENT APPEALS AND INTERFERENCES

Patent Interference No. 105,433 (RT)

ZYMOGENETICS, INC.
(6,528,050),
Junior Party,

v.

LUDWIG INSTITUTE FOR CANCER RESEARCH
and Licentia Ltd.
(09/852,209),
Senior Party.

REDECLARATION - Bd.R. 203(c)

By TORCZON, *Administrative Patent Judge*.

1 A. *Redeclaration of interference*

2 The interference is redeclared in view of the decision on motions. Paper 48.

3 Details of the application, patent, count, and claims designated as corresponding to
4 the count appear under headings E and F of this REDECLARATION.

5 B. *Designation to manage*

6 Administrative Patent Judge Richard Torczon will continue to manage the
7 interference. Bd. R. 104(a).

The STANDING ORDER [SO] (Paper 2) remains in effect.

Priority times are set in Paper 50.

Junior Party

Title: Grow factor homolog ZVEGF3

Charles E. Hart of Woodinville, Washington;

Christopher S. Piddington of Thousand Oaks, California;

Paul O. Sheppard of Granite Falls, Washington;

Kimberly E. Shoemaker of Bellevue, Washington;

Debra G. Gilbertson of Seattle, Washington; and

James W. West of Seattle, Washington.

Senior Party

Application: 09/852,209, filed 10 May 2001

Title: Platelet-derived growth factor C, DNA coding therefor, and uses thereof

Inventors: Ulf Eriksson of Stockholm, Sweden;
Karin Aase of Stockholm, Sweden;
Xuri Li of Stockholm, Sweden;
Annica Ponten of Stockholm, Sweden;
Marko Uutela of Helsinki, Finland;
Kari Alitalo of Helsinki, Finland;
Arne Oestman of Uppsala, Sweden;
Carl-Henrik Heldin of Uppsala, Sweden; and
Christer Betsholtz of Göteborg, Sweden.

F. *Count and claims of the parties*

Count 2

A method for promoting the proliferation of fibroblasts or smooth muscle cells in a mammal comprising administering to said mammal a composition comprising:

1 a protein comprising a first polypeptide disulfide bonded to a
2 second polypeptide, wherein each of said first and second
3 polypeptides is from 111 to 136 amino acid residues in length and
4 comprises residues 235-345 of [6,528,050] SEQ ID NO:2; and a
5 pharmaceutically acceptable vehicle, in an amount sufficient to
6 increase cell proliferation; or

7 a method of stimulating growth of connective tissue or wound
8 healing in a mammal, said method comprising administering to said
9 mammal an effective growth stimulating amount of a polypeptide
10 comprising amino acid residues 230 to 345 of [09/852,209] SEQ ID
11 NO:3.

12
13 The claims of the parties are:

14 ZymoGenetics: 1-15

15 LICR: 36, 46-49, 59, and 60

16 All claims correspond to Count 2.

1 The benefit accorded for Count 2:

2 ZymoGenetics: 09/706,968, filed 6 November 2000;
3 09/541,752, filed 31 March 2000;
4 09/457,066, filed 7 December 1999; and
5 60/111,173, filed 7 December 1998.

6 LICR: 09/852,209, filed 10 May 2001;
7 09/410,349, filed 30 September 1999; and
8 60/108,109, filed 12 November 1998.

cc:

Steven W. Parmelee and Michael T. Rosato, TOWNSEND AND TOWNSEND
AND CREW, LLP, of San Francisco, California, for ZymoGenetics, Inc.

Joseph D. Evans, Michael H. Jacobs, and Thomas H. Haas, CROWELL &
MORING LLP, of Washington, D.C., for Ludwig Institute for Cancer Research and
Licentia Ltd.

Desperтт, Sonja

From: Desperтт, Sonja on behalf of Interference Trial Section
Sent: Friday, March 23, 2007 8:34 AM
To: 'jdevans@crowell.com'; 'mjacobs@crowell.com'; 'mtr@townsend.com'; 'swp@townsend.com'; 'thaas@crowell.com'
Subject: Interference 105433 (RT) Paper No. 49 - Redecларation-Bd.R. 203(c)
Attachments: 105433_049.pdf

3/23/07